Omalizumab, mepolizumab i reslizumab: indicació avaluada; tractament de l'asma greu no controlada en pacients adults
Asthma is a chronic inflammatory disease of the respiratory tract, in which several cells and mediators of inflammation intervene, partly conditioned by genetic factors, which performs with bronchial hyperresponse (HRB) and a variable obstruction at Air flow, totally or partially reversible spontaneously or by medication action. It really is a very heterogeneous disease and is currently talking about a syndrome that groups several clinical phenotypes (clinical entities that share similar manifestations, but probably different etiologies) and endotips 6 (clinical entities that share molecular mechanisms of the disease ). The characterization of asthma includes two key concepts: the severity and control of the disease. The severity of asthma (intermittent, mild, moderate and severe) is determined based on the minimum maintenance maintenance requirements (maintenance steps) to achieve disease control. Control of asthma (well controlled, partially controlled and poorly controlled) is established based on the degree of control of the symptoms, exacerbations and pulmonary function:
Severe asthma; Pharmacological treatment; Adult patients
Omalizumab, mepolizumab i reslizumab: indicació avaluada; tractament de l'asma greu no controlada en pacients adults. Barcelona: Servei Català de la Salut; 2017.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/3659
This item appears in following collections
The following license files are associated with this item: